Multispecific IgG Clearance Molecules Using ASGR1 Recycling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current FcRn inhibitors for treating autoantibody-induced diseases require frequent and high-dose administration due to a rate-limiting endocytosis process, leading to slow depletion of IgGs, and result in off-target effects.
Innovation Solution
Development of multispecific molecules with binding domains that target immunoglobulins and recycling targets like ASGR1, allowing for rapid lysosomal degradation of IgGs, reducing the need for frequent dosing and minimizing off-target effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If FcRn inhibitors are administered to deplete IgGs, then IgG depletion is achieved, but the process is slow and requires frequent high-dose administration
Solution Approach 1:
The patent introduces a multispecific molecule as an intermediary that simultaneously binds to both IgG and ASGR1. This mediator facilitates rapid transfer of IgG to the recycling target, accelerating the depletion process compared to direct FcRn inhibition alone. The multispecific molecule acts as a bridge that enhances the efficiency of IgG clearance.
Solution Approach 2:
The invention combines two functions into a single multisspecific molecule: binding to IgG (via the first binding domain) and binding to ASGR1 (via the second binding domain). This merging of functions allows simultaneous engagement of both targets, creating a synergistic effect that accelerates IgG degradation beyond what either mechanism could achieve alone.
2Quantity of substance
If FcRn inhibitors are used to deplete IgGs, then IgG levels decrease, but off-target effects occur
Solution Approach 1:
The patent applies local quality by creating specificity in the binding domains. The first binding domain is specifically designed to recognize IgG, while the second binding domain is specifically designed to recognize ASGR1. This localized specificity ensures that the multispecific molecule acts only on the intended targets, minimizing off-target effects while maintaining effective IgG depletion.
3Productivity
If endocytosis is used to clear IgGs, then IgG degradation is achieved, but the process is rate-limiting and slow
Solution Approach 1:
The multispecific molecule performs preliminary action by pre-binding to both IgG and ASGR1 before the actual degradation process. This pre-association creates a ready-to-degrade complex that enters the cell and is rapidly processed by the lysosome, eliminating the rate-limiting step of endocytosis that would otherwise slow down the clearance process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The multispecific molecules achieve rapid depletion of IgGs within hours, offering a more effective and targeted treatment for autoantibody-induced diseases with reduced off-target impacts.
Implementation Method 1
Multispecific molecules bind immunoglobulin and a recycling target and result in rapid lysosomal degradation of immunoglobulin
Implementation Method 2
Multispecific molecules bind immunoglobulin and a recycling target and result in rapid lysosomal degradation of immunoglobulin
Implementation Method 3
the recycling target remains bound to the multispecific molecule, and recycles back to the cell surface
Data Source
AI summary
The present invention is directed to multispecific molecules that bind immunoglobulin and a recycling target. Binding immunoglobulin and a recycling target results in degradation of immunoglobulin and in certain embodiments recycling of the multispecific molecule. The multispecific molecules of the present invention are thought to be useful in the treatment of autoantibody-induced diseases.